HRSA Rural Health Clinic
COVID-19 Therapeutic Treatment Program FAQs
- What is the HRSA RHC COVID-19 Therapeutic Treatment Program?
This program provides CMS-certified RHCs free access to COVID-19 therapeutics. HRSA implemented this program to ensure underserved communities and those disproportionately affected by COVID-19 have equitable access to FDA-authorized or approved COVID-19 therapeutics.
- Are RHCs required to participate in this program?
No, eligible RHCs can choose to enroll and register in this program but are not required to do so.
- Which therapeutics are distributed through this program?
Paxlovid and Lagevrio (monulpiravir).
- Who can enroll in this program?
Therapeutics Program enrollment is currently open to CMS-certified Rural Health Clinics enrolled in the HRSA COVID-19 Testing Supply or Vaccine Distribution Programs. For additional information please email RHCTreatment@HRSA.gov.
- Are there any reporting requirements?
RHCs are required to enter the number of therapeutics dispensed (“courses administered”) and inventory/stock on hand (“courses available”) weekly in TPOP. This data should be logged even if your RHC is not placing a new order or the stock on hand is zero.
TPOP also has a wastage report feature for therapeutics to help HRSA keep track of the therapeutics wasted, the number of doses wasted, and understand how they were wasted.
- Can I give therapeutics to other clinics/hospitals?
You may share therapeutics with other HRSA-approved locations that you have an established formal contract or agreement with that meet legal pharmaceutical requirements. Also, you can share stock with other organizations enrolled in this program.